Who Owns Regeneron Pharmaceuticals Company?

Regeneron Pharmaceuticals Bundle

Get Full Bundle:

	PESTLE	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals, a leader in the biopharmaceutical industry, has a complex ownership structure shaped by its founders, early investors, and public shareholders. Its strategic acquisitions, like the May 2025 deal for $256 million to enhance genetics research, underscore its commitment to innovation.

Understanding who holds significant stakes in Regeneron is key to grasping its strategic decisions and future direction. The company's journey from its founding in 1988 to its current status as a major player is marked by significant financial milestones and strategic growth.

Regeneron Pharmaceuticals, Inc., founded in 1988, is an American biotechnology company headquartered in Tarrytown, New York. Its original vision focused on neurotrophic factors, expanding to address serious diseases like eye conditions, cancer, and cardiovascular disorders. As of July 23, 2025, Regeneron's market capitalization stood at approximately $60.48 billion. The company reported full-year 2024 revenues of $14.20 billion, an 8% increase over 2023, and initiated a quarterly dividend of $0.88 per share in February 2025. This financial strength supports its ongoing research and development, including advancements in areas like genetics, which was bolstered by the acquisition of key assets from 23andMe Holding Co. in May 2025 for $256 million. The company's robust pipeline and marketed therapies are a testament to its proprietary technologies, such as VelociSuite, and its strategic focus on innovation. For a deeper dive into the company's market positioning, consider reviewing the Regeneron Pharmaceuticals PESTEL Analysis.

Regeneron Pharmaceuticals ownership traces back to its founding in 1988 by a trio of scientific minds. Dr. Leonard S. Schleifer, a neurologist, and Dr. George D. Yancopoulos, a molecular immunologist, were the primary drivers, establishing the company in New York. A third co-founder, neuroscientist Eric M. Shooter, also played a key role in the early stages.

Founding Visionaries Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos co-founded Regeneron Pharmaceuticals in 1988. Their scientific backgrounds in neurology and molecular immunology shaped the company's early direction. Early Operations Dr. Schleifer initiated the company from his New York City apartment. By 1989, Dr. Yancopoulos joined as Chief Scientific Officer, and operations were established in Tarrytown, New York. Founder Ownership While precise initial equity splits are not public, Dr. Schleifer and Dr. Yancopoulos have maintained significant ownership. This reflects a strong founder-led ethos that continues to influence the company. Significant Stakes As of recent reports, Dr. Schleifer and Dr. Yancopoulos hold substantial stock. Their holdings are valued at approximately $1.3 billion and $900 million, respectively. Early Support The U.S. Department of Health and Human Services provided a grant investment of $14.9 million in August 2010. This funding came well after the company's initial founding phase. Founding Philosophy Information on very early angel investors or friends and family stakes from 1988 is not readily available. The founding team's vision emphasized a long-term scientific approach, a key aspect of Regeneron's culture.

The early ownership structure of Regeneron Pharmaceuticals was heavily influenced by its founders, Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos. Their commitment to a science-first approach has been a defining characteristic since the company's inception in 1988. This foundational philosophy continues to guide Regeneron's strategic direction and research endeavors, as detailed in the Brief History of Regeneron Pharmaceuticals.

Key Founders and Their Roles

Regeneron was co-founded by Dr. Leonard S. Schleifer, a neurologist, and Dr. George D. Yancopoulos, a molecular immunologist. Eric M. Shooter, a neuroscientist, also served as a co-founder and board member until 2014.

• Dr. Leonard S. Schleifer: Initiated operations and remains a significant shareholder.
• Dr. George D. Yancopoulos: Joined as Chief Scientific Officer and holds substantial stock.
• Eric M. Shooter: Contributed as a co-founder and board member.
• Founding ethos: Emphasis on a long-term scientific approach.

Regeneron Pharmaceuticals SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Regeneron Pharmaceuticals, Inc. went public on April 2, 1991, marking the beginning of its journey from a founder-centric startup to a major biopharmaceutical company. Its market value has seen substantial growth, reaching over $1 billion by 2010 and currently standing at $59.14 billion as of July 1, 2025. This evolution in market capitalization reflects significant changes in its ownership structure over the decades.

The ownership landscape of Regeneron Pharmaceuticals has transformed considerably since its inception. Initially driven by its founders, the company now boasts a robust base of institutional investors. As of March 31, 2025, a significant majority, approximately 87.81% of Regeneron's total shares outstanding, are held by institutional owners. This includes major entities like Vanguard Group Inc., BlackRock, Inc., and Fmr LLC, among others, who collectively hold millions of shares. This high level of institutional backing often influences corporate governance and strategic decisions, underscoring the importance of understanding who owns Regeneron and their stake in its future.

Understanding Regeneron's Shareholder Structure

Regeneron Pharmaceuticals operates with a dual-class stock structure, a critical element influencing voting power. This structure, in place since the company's IPO, has seen shifts in the proportion of voting rights held by different classes of shares over time.

• Regeneron Pharmaceuticals ownership is characterized by a significant presence of institutional investors.
• As of March 31, 2025, 2,345 institutional owners held over 113 million shares.
• The dual-class stock structure impacts voting power, with Class A shares representing a decreasing percentage of total shareholder votes since the IPO.
• Understanding the history of Regeneron Pharmaceuticals ownership is key to grasping its current shareholder dynamics.
• Key individuals and institutional investors play a crucial role in Regeneron company ownership.

The company's dual-class stock structure, a feature since its IPO, significantly shapes voting power. While the general principle is 'one-share, one-vote,' this structure introduces nuances. Initially, Class A stock represented about 95% of total shareholder votes. However, by the record date for the 2023 Annual Meeting, Class A shares had decreased to 1.8 million, accounting for approximately 14% of total shareholder votes, a notable reduction from the 10.9 million shares at the IPO. This gradual dilution of super-voting power, while still requiring Class A shareholder approval for certain changes, highlights the evolving control dynamics. This shift is important for anyone looking to understand who controls Regeneron Pharmaceuticals' voting shares and how that power is distributed. For a deeper dive into the company's market position, consider the Target Market of Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Regeneron Pharmaceuticals' board of directors is composed of experienced individuals, including its co-founders, who remain actively involved in the company's strategic direction. As of 2025, the board features key figures like Leonard S. Schleifer, MD, PhD, and George D. Yancopoulos, MD, PhD, alongside other distinguished members, reflecting a blend of scientific and business acumen.

Regeneron employs a dual-class share structure, a critical element in understanding Regeneron Pharmaceuticals ownership and who controls Regeneron. This structure assigns ten votes per share to Class A stock and one vote per share to common stock. Although Class A shares represent approximately 14% of the total votes as of the 2023 Annual Meeting, their concentrated voting power significantly influences corporate decisions. This arrangement ensures that holders of Class A stock, historically including the founders, maintain substantial control over the company's long-term strategy, a key aspect of Regeneron company ownership.

Voting Power Dynamics

The dual-class share structure at Regeneron Pharmaceuticals ownership grants disproportionate voting power to Class A shareholders. This structure has been a subject of discussion among institutional investors regarding shareholder equality.

• Class A shares carry ten votes per share, while common stock has one vote per share.
• As of the 2023 Annual Meeting, Class A shares accounted for about 14% of total voting power.
• Changes to Class A voting rights require approval from a majority of Class A shareholders.
• Concerns have been raised by entities like DWS Investment GmbH about the lack of a sunset provision in the multi-class structure, advocating for a 'one-share, one-vote' principle.
• Despite these concerns, the founder's control remains largely intact due to the protections afforded by the Class A shares, impacting Regeneron stock holders.

Regeneron Pharmaceuticals Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Regeneron Pharmaceuticals has seen a dynamic shift in its ownership landscape over the past few years, characterized by substantial capital returns to shareholders and strategic acquisitions. The company's board has actively managed its capital structure, reflecting a commitment to enhancing shareholder value.

In addition to returning capital, the company has strategically expanded its operations and research capabilities. These moves are designed to bolster its long-term growth prospects and solidify its position in the biopharmaceutical industry. The company's focus on innovation and strategic investment underscores its commitment to advancing healthcare solutions.

Strategic Acquisitions and Investments

Regeneron acquired 2seventy bio's R&D pipeline in 2024, creating Regeneron Cell Medicines. In May 2025, the company successfully bid $256 million for substantially all of 23andMe Holding Co.'s assets, including its Personal Genome Service, pending Q3 2025 closure.

Venture Capital and Future Growth

In April 2024, Regeneron committed $500 million over five years to Regeneron Ventures. This fund targets investments in promising biopharmaceutical, healthcare, and health technology companies.

Ownership Trends and Influence

Institutional ownership stands at a significant 87.81% as of March 2025, indicating strong backing from major financial entities. While founders retain influence through a dual-class share structure, there have been no announcements regarding privatization or major leadership shifts beyond recent board transitions.

Market Position and Shareholder Value

The company's aggressive share buyback programs are a key strategy to support its stock price and enhance overall shareholder value. This approach, combined with strategic growth initiatives, positions Regeneron for continued market engagement and performance. Understanding the Competitors Landscape of Regeneron Pharmaceuticals provides further context to these strategic moves.

Regeneron Pharmaceuticals Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔